Beam Therapeutics Newsroom

A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $42 to $80

Futu NewsDec 10 21:01

Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow JonesDec 10 01:50

Beam Therapeutics Analyst Ratings

BenzingaDec 10 01:40

Promising Early Data and Innovative Approaches Lead to Buy Rating for Beam Therapeutics

TipRanksDec 10 01:30

J.P. Morgan Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $48

Futu NewsDec 9 19:33

Analysts' Top Healthcare Picks: Stoke Therapeutics (STOK), Beam Therapeutics (BEAM)

TipRanksDec 9 19:32

William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating

Futu NewsDec 9 18:32

William Blair Remains a Buy on Beam Therapeutics (BEAM)

TipRanksDec 9 18:06

H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80

Futu NewsNov 7 01:32

Beam Therapeutics Is Maintained at Sector Perform by RBC Capital

Dow JonesNov 7 00:10

Scotiabank Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Cuts Target Price to $24

Futu NewsNov 6 21:31

A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $31 to $69

Futu NewsNov 6 21:08

Beam Therapeutics Analyst Ratings

BenzingaNov 6 20:29

JonesTrading Sticks to Their Hold Rating for Beam Therapeutics (BEAM)

TipRanksNov 6 05:27

Buy Rating Affirmed for Beam Therapeutics Due to Promising BEAM-101 Developments in Sickle Cell Disease Treatment

TipRanksNov 5 23:40

William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating

Futu NewsOct 31 18:31

Beam Therapeutics Analyst Ratings

BenzingaOct 16 22:32

Scotiabank Initiates Beam Therapeutics at Sector Perform With $24 Price Target

MT NewswiresOct 16 20:23

Beam Therapeutics Price Target Maintained With a $27.00/Share by RBC Capital

Dow JonesSep 19 21:31

RBC Capital Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Maintains Target Price $27

Futu NewsSep 19 19:31